Mean change in the co-primary endpoint : FPG, HDL-C and triglyceride levels. From baseline to end of treatment [clinicaltrials_resource:cc7b86630380b14253d2f63f9a7c6e51]
Administration of one tablet containing 20 mg of Rimonabant
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Mean change in the co-primary endpoint : FPG, HDL-C and triglyceride levels. From baseline to end of treatment [clinicaltrials_resource:cc7b86630380b14253d2f63f9a7c6e51]
Administration of one tablet containing 20 mg of Rimonabant
Bio2RDF identifier
cc7b86630380b14253d2f63f9a7c6e51
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:cc7b86630380b14253d2f63f9a7c6e51
measure [clinicaltrials_vocabulary:measure]
Mean change in the co-primary endpoint : FPG, HDL-C and triglyceride levels.
time frame [clinicaltrials_vocabulary:time-frame]
From baseline to end of treatment
description
Administration of one tablet containing 20 mg of Rimonabant
identifier
clinicaltrials_resource:cc7b86630380b14253d2f63f9a7c6e51
title
Mean change in the co-primary ...... m baseline to end of treatment
@en
type
label
Mean change in the co-primary ...... b86630380b14253d2f63f9a7c6e51]
@en